therapeutic testing by providing greater resolution between normal and dystrophic muscle function (Sacco et al., 2010; Chandrasekharan et al., 2010) . For example, a variety of structurally distinct microdystrophins (miniaturized versions of dystrophin that can be efficiently delivered to dystrophic muscles using adenoassociated viral vectors) are being tested for use in gene therapy for DMD (Muir and Chamberlain, 2009 ). However, it can be challenging to identify the constructs that work best in ameliorating the relatively mild pathophysiology of mouse mdx mutant muscles. The stronger phenotype of the mdx/mTR doublemutant mice provides a better background for testing therapies. This issue is significant because even subtle functional changes in mdx muscle function could translate into significant quality of life issues for patients. Similar arguments can be made for testing almost all types of experimental DMD therapies.
One limitation of the new mdx/mTR mouse model is the somewhat elaborate breeding scheme required to achieve the desired genotype. Given the significant therapeutic advances achieved using the current mdx models, it should be possible to perform initial or routine testing in the standard mdx strains and use the more severely affected double-mutant strains for secondary and follow-up testing. Nevertheless, the increased power of analysis afforded by the newer mutations may reduce the number of large animal model studies needed for preclinical testing of DMD therapeutics and thereby accelerate the development of a treatment for DMD.
Two papers in this issue of Cell (Paradis-Bleau et al., 2010 and Typas et al., 2010) report that the lipoproteins LpoA and LpoB are required for the synthesis of cell walls in Escherichia coli. Attached to the bacterial outer membrane, these new cell wall components regulate penicillin-binding proteins located at the inner membrane.
Cell walls protect bacteria against osmotic lysis. In Gram-negative bacteria, this enclosing envelope consists of a cytoplasmic membrane surrounded by an outer membrane. Sandwiched between the two membranes is the peptidoglycan polymer, the rigid scaffolding that gives the wall its strength. Peptidoglycan consists of repeating linear polymers of N-acetylglucosamine and N-acetylmuramic acid linked together via short oligopeptide chains. Because the enzymes that synthesize peptidoglycan are the targets of one of the most important classes of antibiotics, the b-lactams, there is great interest in understanding their activities and regulation. In this issue of Cell, two groups (Paradis-Bleau et al., 2010; Typas et al., 2010) identify new components of the cell wall synthetic machinery in E. coli, adding unexpected complexity to a process that we thought we understood fairly well.
The final stage of peptidoglycan synthesis depends on the high molecular weight penicillin-binding proteins (PBPs), which polymerize disaccharide precursors into glycan chains and then covalently crosslink the chains to form mature peptidoglycan (Hö ltje, 1998; Margolin, 2009 ). In Gram-negative bacteria, penicillinbinding proteins are anchored to the outer face of the cytoplasmic (inner) membrane and synthesize peptidoglycan in the periplasmic space between the inner and outer membranes ( Figure 1 ). Studies thus far have suggested that penicillin-binding proteins are constitutively active and largely unregulated, though other proteins may dictate their cellular position (Margolin, 2009; Pichoff and Lutkenhaus, 2007) . Now, Paradis-Bleau et al. and Typas et al. find that, in E. coli (a Gram-negative bacterium), the two main high molecular weight penicillin-binding proteins, PBP 1a and PBP 1b, are each activated by specific outer-membrane lipoproteins, LpoA and LpoB, respectively ( Figure 1A ). Although these lipoproteins are not homologous to one another, they appear to perform similar functions because bacterial survival requires the presence and activity of at least one PBP-Lpo pair. In vitro, Typas et al. find that PBP 1a and PBP 1b can synthesize peptidoglycan but that LpoA and LpoB enhance their activities. However, Paradis-Bleau et al. find that in vivo overproduction of either PBP 1a or PBP 1b does not rescue defects caused by deleting an Lpo protein, suggesting that the lipoproteins may be required for enzymatic function and do not merely enhance PBP activity. A potential explanation for this apparent discrepancy may be that, in vivo, peptidoglycan is not distributed correctly in the absence of the Lpo lipoproteins. Alternatively, the in vitro system may artificially activate the PBPs, or perhaps a negative regulator that exists in vivo necessitates lipoprotein involvement.
The PBP1b-LpoB complex performs at least one function that PBP1a-LpoA cannot. During bacterial cell division, all three envelope components constrict as a unit as the division septum invaginates to form the poles of two new daughter cells. This process requires tethering of the outer membrane to the underlying peptidoglycan layer and to the inner membrane via a group of proteins known as the Tol-Pal system (Gerding et al., 2007) . Although E. coli cells survive the loss of any one of these proteins (i.e., PBP 1a, PBP 1b, LpoA, LpoB, or Tol-Pal), Typas et al. find that the cells lyse when both the Tol-Pal and the PBP1b-LpoB complexes are deleted. These findings suggest that PBP1b-LpoB, but not PBP1a-LpoA, can replace the tethering function of Tol-Pal during cell division ( Figure 1B) . However, the functional significance of this finding is unclear because E. coli cells still grow and divide in the absence of PBP1b-LpoB, indicating that PBP1a-LpoA can also synthesize peptidoglycan during septation. Nevertheless, the results suggest that bacteria without a Tol-Pal system may employ PBP1b-LpoB analogs to tether the outer membrane to the septum.
To determine whether the functions of the Lpo proteins depend on their localization to the outer membrane, both ParadisBleau et al. and Typas et al. create Lpo fusions that localize to the inner-instead of outer-membrane ( Figures 1C and 1D) . In this configuration, LpoA does not activate PBP 1a ( Figure 1D ), suggesting that a productive pairing requires another outer-membrane component or that the inner-membrane location prevents a proper three-dimensional interaction. Surprisingly, LpoB can still activate PBP 1b ( Figure 1C) , indicating that the PBP1b-LpoB interaction is less dependent on exact subcellular localization. However, as expected given the tethering role of the Tol-Pal proteins, the innermembrane PBP1b-LpoB complex no longer complements the defect of a mutant lacking the Tol-Pal system ( Figure 1C) .
Although all bacteria that synthesize peptidoglycan express bifunctional PBPs that polymerize and then crosslink glycan chains, the specific PBP-lipoprotein combinations described in the current papers are restricted to the g-proteobacteria lineage of Gram-negative bacteria, and obvious LpoB homologs are restricted further to the Enterobacteriaceae, a bacterial subgroup commonly found in vertebrate intestines. Why is the PBP-Lpo combination not more widespread? One possibility is that the Enterobacteriaceae, by virtue of their physiological niche or for other unknown reasons, need this extra device to regulate peptidoglycan synthesis. Another possibility is that other bacteria use accessory factors unrelated to the Lpo proteins to regulate peptidoglycan synthesis. Either way, the results suggest that peptidoglycan synthesis is subject to external controls that have heretofore escaped detection, and it is thus worth investigating how such regulation may be accomplished in other organisms.
Why are these results surprising? First, LpoA and LpoB are the first regulators of the high molecular weight penicillinbinding proteins. It is likely that such regulation exists to meet some physiological need, which awaits discovery. Second, it is not only their existence but their location that is surprising. The fact that the lipoproteins are tethered to the outer membrane means they must cross the peptidoglycan layer to make contact with the penicillin-binding proteins, which are tethered to the inner membrane ( Figure 1 ). Paradis-Bleau et al. speculate that the lipoproteins may guide peptidoglycan synthesis along defined tracks. Typas et al. suggest that the lipoproteins may control the rate or location of new synthesis by reaching through holes in the peptidoglycan to contact and activate the PBPs, which are tethered to the inner membrane on the other side of the wall. There are, no doubt, other possibilities.
Finally, the reports raise many questions. Do Gram-positive bacteria, which don't have an outer membrane but have a much thicker peptidoglycan layer, also express proteins that regulate penicillinbinding proteins? And if so, where in the cell are these proteins located? Can cell wall synthesis be reconstituted in vitro? Are there any other important cell wall agents that we don't know about, and might any of these new components serve as targets for antibiotics? Future studies to address these and other questions should reveal whole new vistas of the bacterial cell wall.
